Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilostazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 8/20 | 0.82 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | THPO | P40225 | 1/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.82 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilostazol SCHEMBL5798394 | 0.91 | PDE3B (0.92) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL16128 | 0.91 | PDE3B (1.00) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL29389547 | 0.91 | PDE3B (1.00) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL1818013 | 0.91 | PDE3B (1.00) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL825715 | 0.90 | PDE3B (0.78) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL5798390 | 0.89 | PDE3B (0.93) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| SCHEMBL7307973 | 0.88 | PDE3B (0.94) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| Cilostazol SCHEMBL5798372 | 0.86 | PDE3B (0.81) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| SCHEMBL30151170 | 0.84 | PDE3B (0.83) | PDE3BPDE3AALDH1A1MEN1ABCC4 | |
| SCHEMBL29701270 | 0.84 | PDE3B (0.83) | PDE3BPDE3AALDH1A1MEN1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779146-B2 | Cilostazol cocrystals and compositions | NUFORMIX LIMITED (GB) | 2014-07-15 | — | — | US | claimed |
| US-20130203806-A1 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2013-08-08 | — | — | US | claimed |
| WO-2011158110-A2 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2011-12-22 | — | — | WO | claimed |
| CN-102933205-B | Cilostazol cocrystals and compositions | NUFORMIX LTD | 2014-08-13 | — | — | CN | disclosed |
| US-8779146-B2 | Cilostazol cocrystals and compositions | NUFORMIX LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779146-B2 | Cilostazol cocrystals and compositions | NUFORMIX LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20130203806-A1 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203806-A1 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| CN-102933205-A | Cilostazol cocrystals and compositions | NUFORMIX LTD | 2013-02-13 | — | — | CN | disclosed |
| WO-2011158110-A3 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011158110-A2 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011158110-A2 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | NUFORMIX LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203806-A1 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS | GUCY1A1, GUCY1A2, PDE3A | PDE3A 3/4885PDE3B 7/4885ALDH1A1 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.